A Phase I/II, Prospective, Open-Label Study to Determine the Safety and Efficacy of CC-4047 in Patients With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis.
Phase of Trial: Phase I/II
Latest Information Update: 31 Jul 2018
At a glance
- Drugs Pomalidomide (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- 28 Jun 2018 Planned End Date (expected last completion date for patients who have remained in follow-up post-trial completion) changed from 1 May 2013 to 1 Dec 2018.
- 24 Jan 2011 Planned end date changed from 1 May 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
- 28 Jul 2010 Planned end date changed from 1 May 2011 to 1 May 2012 as reported by ClinicalTrials.gov.